Ranbaxy, Cipher Agree To Expand Acne Drug License To Brazil
This article was originally published in PharmAsia News
Ranbaxy Laboratories and Cipher Pharmaceuticals have signed an agreement extending their distribution and marketing contract for the Canada drug maker's Absorica (isotretinoin) acne treatment in Brazil.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.